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microRNAs are a class of small, non-coding RNAs 
that regulate gene expression at the post-transcriptional 
level. By blocking the stability and translation of protein-
coding mRNAs, microRNAs impact most biological 
systems in health and disease, including the development 
and the function of the immune system [1]. A recent study 
by Marcais et al. has added new insights how microRNAs 
guide critical decisions by T lymphocytes [2].
T cells receive constant inputs from their 
surroundings - the challenge is that T cells must tolerate 
our own healthy cells and harmless commensals, yet 
mount vigorous immune responses against potentially 
harmful pathogens, transformed cells and other threats. 
If this discrimination fails, T cells may mistakenly attack 
healthy cells and cause autoimmunity, or they may fail to 
protect us from harm. A tried and tested strategy is that T 
cells tolerate signals that exclusively engage their T cell 
receptor (TCR), but go after signals that simultaneously 
engage the TCR and a set of co-stimulatory receptors that 
indicate the presence of tissue damage or inflammation 
[3]. In isolation, TCR signals trigger a state of 
unresponsiveness called anergy, whereas combined inputs 
through the TCR and co-stimulatory receptors trigger T 
cell activation, proliferation and the acquisition of effector 
functions [3]. The cytokine interleukin 2 (IL-2) is critical 
in this context: full T cell activation is required for T cells 
to produce IL-2. In turn, IL-2 promotes T cell activation 
and can override the induction of anergy [3].
To probe the role of microRNAs in T cell activation, 
Marcais et al. [2] generated CD4 T cells that were 
genetically deficient of the RNase III enzyme Dicer, 
which is required for the biogenesis of most microRNAs. 
Interestingly, these microRNA-deficient T cells became 
fully activated in response to isolated TCR signals, which 
would have rendered normal T cells anergic [2]. Analysis 
of the underlying mechanisms showed that the resistance 
of microRNA-deficient T cells to anergy was due to 
their ability to make and secrete IL-2 in the absence of 
co-stimulatory signals. As a result, microRNA-deficient 
T cells could even override anergy induction in normal 
bystander T cells through the paracrine action of IL-2 [2].
Detailed analysis of the signaling machinery in 
microRNA-deficient T cells revealed several lesions, 
including the abnormally strong and prolonged 
activation of mTORC1 and mTORC2 (‘mTOR’ stands 
for ‘mechanistic target of rapamycin’ and ‘C’ stands 
for ‘complex’). mTOR complexes integrate signaling 
pathways to regulate a broad range of cellular functions. 
A number of mTOR complex components were already 
known targets of microRNA regulation in normal [4] and 
in cancer cells [5], and the authors demonstrated that the 
expression of Mtor and Rictor was regulated by Let-7, 
Mir-16 and most likely other microRNAs in T cells [2]. 
In the absence of microRNAs, Mtor and Rictor were 
overexpressed, but was this overexpression responsible 
for uncontrolled IL-2 production by micro-RNA-deficient 
T cells? To address this question, Marcais et al. [2] used 
genetics to introduce one defective Mtor allele and one 
defective Rictor allele into Dicer-deficient T cells. As a 
result, Mtor and Rictor proteins were derived from a 
single Mtor and a single Rictor allele. This approach 
compensated for the lack of post-transcriptional control, 
and restored near-normal levels of Mtor and Rictor 
proteins to microRNA-deficient T cells. Critically, 
reversing the overexpression of Mtor and Rictor also 
reduced the ability of microRNA-deficient T cells to 
produce IL-2 in the absence of co-stimulation [2]. This 
work supports the idea that microRNAs help T cells 
decide between activation and anergy, at least in part by 
controlling the precise expression of cellular signaling 
components (Figure 1). 
In this context it is of note that recent data 
suggest an additional role for microRNAs in developing 
thymocytes, the precursors of mature T cells [6]. Here, 
microRNAs can make cellular responses more predictable 
by reducing cell-to-cell variability. Whether or not this 
principle applies in mature T cells has not yet been 
examined. Nevertheless, given that the inappropriate 
production of IL-2 can override anergy in bystander cells, 
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Figure 1: In wild type CD4 T cells, IL-2 secretion 
requires the coincidence of 2 signals through the 
TCR and through co-stimulatory receptors (left). In 
microRNA-deficient T cells, TCR signals are amplified by 
increased expression of Mtor components and increased mTOR 
activation (right). Through a series of intermediate steps that 
may involve NF-kappaB and other factors, this mechanism leads 
to IL-2 secretion in the absence of co-stimulatory signals and to 
autocrine and paracrine T cell activation.
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it is interesting to reflect on the possibility that ‘outlier’ 
cells might destabilise immunological responses by 
inappropriately IL-2 production. However, sustained T 
cell expansion may require a critical number of activated 
T cells at the outset [7]. Hence, in addition to microRNAs, 
the immune system is ‘buffered’ by additional mechanisms 
that confer stability and ensure that important decisions 
are made based on consensus. 
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